Provided by Tiger Trade Technology Pte. Ltd.

LISATA THERAPEUTICS INC

1.74
+0.270018.37%
Post-market: 1.800.0600+3.45%19:58 EDT
Volume:3.04M
Turnover:5.35M
Market Cap:15.68M
PE:-1.06
High:2.56
Open:2.50
Low:1.50
Close:1.47
52wk High:5.07
52wk Low:0.9875
Shares:9.01M
Float Shares:6.49M
Volume Ratio:19.79
T/O Rate:46.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6418
EPS(LYR):-1.9100
ROE:-101.66%
ROA:-56.74%
PB:1.90
PE(LYR):-0.91

Loading ...

Lisata Therapeutics Acquires Marea Therapeutics in Pipeline Pivot Toward Cardioendocrine Drugs

Reuters
·
Yesterday

Lisata Therapeutics, - Acquisition Structured as Stock-for-Stock Deal with Lisata Common and Series C Preferred Stock

THOMSON REUTERS
·
Yesterday

Lisata Therapeutics, - Post-Deal, Lisata Holders Own 2.39%, Marea Holders 59.54%, Investors 38.07% of Common Stock

THOMSON REUTERS
·
Yesterday

Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement

THOMSON REUTERS
·
Yesterday

Lisata Therapeutics, - to Use Net Proceeds to Advance Mar001/005 and Mar002 with Topline Phase 2 Data Expected Q4 2027

THOMSON REUTERS
·
Yesterday

Lisata Therapeutics, - Investors to Receive 150,867.995 Series C Preferred Shares at $1,491.37 Per Share

THOMSON REUTERS
·
Yesterday

NASDAQ Trade Halt Halt News Pending at 07:55 Am

Reuters
·
Yesterday

U.S. Stocks on the MOVE-Expeditors International, Waters, Wayfair

Reuters
·
Aug 05

Lisata Therapeutics provides update following termination of Kuva Labs merger

TIPRANKS
·
Aug 04

Lisata Therapeutics Sues Kuva Labs over Breached Merger Agreement, Seeks $2 Million Fee

Reuters
·
Aug 04

Lisata Therapeutics - Eliminates Executive Vice President of R&D and Chief Medical Officer Position

THOMSON REUTERS
·
Aug 04

Lisata Therapeutics - Implements Reduction in Force of About 72% of Full-Time Employees

THOMSON REUTERS
·
Aug 04

Lisata Therapeutics Provides Update Following Termination of Merger Agreement

THOMSON REUTERS
·
Aug 04

Lisata Therapeutics - Seeks $2 Mln Termination Fee from Kuva Under Merger Agreement

THOMSON REUTERS
·
Aug 04

Lisata Therapeutics - Board Continues to Evaluate Strategic Alternatives to Enhance Stockholder Value

THOMSON REUTERS
·
Aug 04

Lisata Therapeutics - Files Suit Against Kuva Labs Seeking Damages for Stockholders

THOMSON REUTERS
·
Aug 04

Lisata Therapeutics Cuts Workforce About 72% in Reorganization

Reuters
·
Aug 04

Lisata Therapeutics - Estimates $1.20 Mln of Costs Related to Workforce Reduction Through Qtr Ending Sept 30, 2026 - SEC Filing

THOMSON REUTERS
·
Aug 04

Lisata Therapeutics - on Aug 3, Approved Reduction in Workforce by About 72% Effective Immediately - SEC Filing

THOMSON REUTERS
·
Aug 04

Lisata Therapeutics - Terminates Kristen K. Buck as Evp of R&D and Chief Medical Officer Effective Aug 3, 2026 - SEC Filing

THOMSON REUTERS
·
Aug 04